Source: Pharmaphorum
Behind every breakthrough therapy and every promising clinical trial result is a foundation forged in laboratories – where diagnostic science, assay development, and biomarker validation are quietly powering the pipeline of modern medicine. As professionals working in labs and clinical services, we support innovation by operationalising it.
Today, that role is more critical than ever. Historically, the National Institutes of Health (NIH) and other public institutions have funded and coordinated much of the early-stage research that drives drug development; however, recent political and regulatory decisions have cast doubt on the stability of this support. In the meantime, demand for new treatments has continued to grow, placing enormous pressure on the private sector to fill the gap.
But research alone doesn’t deliver outcomes. The path from biomarker discovery to regulatory approval and clinical use is long and complex, and the clinical lab is where a significant amount of that critical translational work happens. As public funding becomes more uncertain, lab and clinical services professionals are increasingly being called on to help pharma, biotech, and diagnostics companies maintain, and accelerate, momentum.
Related Posts
Industry Insights: Multi-omic Diagnostics
Multi-omic diagnostics are reshaping how researchers and clinicians approach complex diseases, offering deeper biological insights through the integration of multiple data types. In this interview with The Pathologist, industry experts…
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…